Esmeron

Rocuronium Br

Adjunct to general anesth to facilitate tracheal intubation during routine & rapid sequence induction; provide skeletal muscle relaxation during surgery. Adjunct in ICU to facilitate intubation & mechanical ventilation.

Individualized dosage. Given IV either by bolus inj or continous infusion. Tracheal intubation 0.6-1 mg/kg. Maintenance dose: 0.15 mg/kg. Geriatric patients & hepatic &/or biliary tract disease &/or renal failure patients 0.6 mg/kg during routine anesth. Maintenance: 0.075-0.1 mg/kg. Continuous infusion Loading dose: 0.6 mg/kg. Infusion rate: 0.3-0.6 mg/kg/hr. Geriatric patients & hepatic &/or biliary tract disease &/or renal failure patients Infusion rate: 0.3-0.4 mg/kg/hr.

Hypersensitivity to rocuronium or Br ion.

Ventilatory support is mandatory until adequate spontaneous respiration is restored. Consider use of reversal agent in cases where residual curarization may occur. Previous anaphylactic reactions to neuromuscular blocking agents. Hepatic &/or biliary tract & renal diseases. Prolonged circulation time eg, CV disease, old age & edematous state. Patients w/ neuromuscular disease or after poliomyelitis. Hypothermia, obesity, burns. Hypokalaemia, hypermagnesemia, hypocalcemia, hypoproteinemia, dehydration, acidosis, hypercapnia, cachexia. Correct severe electrolyte disturbances, altered blood pH or dehydration when possible. Monitor neuromuscular transmission during therapy. Myopathy may occur w/ long-term therapy. Delay administration if suxamethonium is used for intubation. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn (facilitating tracheal intubation conditions, during rapid sequence conditions; mechanical ventilation in the intensive care). Elderly (facilitating mechanical ventilation in the intensive care).

Inj site pain reaction, changes in vital signs, prolonged neuromuscular block.

Increased effects w/ anaesth, suxamethonium, long-term concomitant use w/ corticosteroids; antibiotics (aminoglycoside, lincosamide, polypeptide & acylamino-penicillin antibiotics), diuretics, quinidine & quinine, Mg salts, Ca channel blocking agents, lithium salts, lidocaine IV, epidural bupivacaine, phenytoin or β-blocking agents. Decreased effect w/ prior chronic administration of phenytoin or carbamazepine; gabexate, ulinastatin. Attenuation or potentiation of neuromuscular block w/ non-depolarizing neuromuscular blocking agents & suxamethonium.

Neuromuscular Blocking Agents

M03AC09 - rocuronium bromide ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.

D